Josua Jordi

Chief Executive Officer at EraCal

Josua Jordi is the CEO and co-founder of EraCal Therapeutics and is in charge of the vision, execution & lead of EraCal since its inception. EraCal develops a novel oral-active anti-obesity drug with superior efficacy & tolerability. An ambitious team with world-class advisors leads the development of this first-in-class appetite suppressor, called Era-379, based on a new mechanism of action. Josua is a trained biochemist from ETH Zurich and completed a Ph.D. in physiology at the University of Zurich. He developed EraCal’s platform as a postdoctoral fellow at Harvard University. The platform forms the basis of a research collaboration with Novo Nordisk and Nestlé Health Science.